COVID-19 Vaccination prevents development of long Covid: BMJ

The breakdown of vaccine effectiveness by dosage found that individuals who received one dose showed 21% effectiveness against PCC, while those with two doses demonstrated a robust 59% reduction in risk. Individuals who received three or more doses experienced an even more significant reduction, with a vaccine effectiveness of 73%.

The study adjusted for various factors, including age, sex, comorbidities, healthcare contacts, socioeconomic factors, and the dominant virus variant at the time of infection. These results underscore the crucial role of primary COVID-19 vaccination in mitigating the population burden of post-COVID conditions.

Despite the positive findings, the study emphasizes the need for ongoing caution and adherence to evidence-based, standard-of-care treatments. While the association between COVID-19 vaccination and reduced PCC risk is strong, researchers call for continued research, especially large-scale clinical trials, to further solidify these conclusions and address any remaining uncertainties.

Reference:

Lundberg-Morris, L., Leach, S., Xu, Y., Martikainen, J., Santosa, A., Gisslén, M., Li, H., Nyberg, F., & Bygdell, M. (2023). Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study. In BMJ (p. e076990). BMJ. https://doi.org/10.1136/bmj-2023-076990